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CHRONIC REJECfION is a serious complication of 
orthotopic liver transplantation (OLT) and is a major 
cause of late hepatic allograft failure. Risk factors leading 
to the development of chronic rejection have been identi-
fied. Two of these are lack of response to acute rejection 
therapy and allograft cytomegalovirus (CMV) infection.1- 3 
However, many patients develop chronic rejection without 
any identifiable risk factor. Furthermore. the intrinsic 
mechanism involved in the development of chronic rejec-
tion is not fully understood. In general. chronic rejection is 
a progressive disease but there are instances where it 
appears to reverse or stabilize over time.~·5 
Hepatitis B virus (HBV) and hepatitis C virus (HCV) 
infections are major causes of end-stage liver disease. Both 
infections persist after OLT leading to recurrence of hep-
atitis in many patients. When the allograft is infected with 
either of these viruses. it may be difficult to distinguish 
histopathologically between hepatitis and rejection.6 We 
postulated that development of posttransplant hepatitis B 
or C may influence the development of chronic rejection 
after liver OLT. 
MATERIALS AND METHODS 
From May 1. 1987 to July 31. 1989.738 adults underwent OLT at 
our institution and received cyclosporine (eyA) and steroids as 
primary immunosuppression. Of these patients 120 (16%) died 
during the first 2 months after OLT. The remaining 618 patients 
served as the study population with a mean = SO follow.up of 
1.192 = 493 days. The histopathologic criteria for posttransplant 
hepatitis and chronic rejection have been described els.:where.o-~ 
Tu investigate whether development of chronic rejection was 
related to a decrease in the amount of immunosuppression given. 
we evaluated the level of CyA (whole blood TOX) and the doses of 
eyA and steroids adjusted to weight at 30. 60, 90. 180. 360. 540. and 
720 days after OLT. 
RESULTS 
Table 1 shows the pretransplant diagnosis and the incidence 
of posttransplant B. non-A non-B, and CMV hepatitis and 
chronic rejection in the study population. Chronic rejection 
developed in 118 patients at 528 :!: 398 days after OLT. 
Three-year patient and graft survival in patients who devel· 
oped chronic rejection was 68% and 55%. respectively. 
whereas in those patients who did not experience chronic 
rejection they were 84% and 82%, respectively (Kaplan. 
Meier: P < .01; Figs 1,2). 
The incidence of chronic rejection in patients who did not 
experience B. non-A non-B. and CMV hepatitis was 13% 
(55 of 418). In contrast. the incidence of chronic rejection 
was 27% (18 of 66) in patients with CMV hepatitis, 40% (45 
of 112) in patients with B. non-A non-B hepatitis. and 55% 
(12 of 22) in patients with both CMV and B or non-A non-B 
hepatitis (Chi-Square test: P < .0001). The relative risk 
(odds ratio) of developing chronic rejection was 2.48 in 
patients with CMV hepatitis. 4.43 in B. non-A non-B 
hepatitis. and 7.92 in CMV and B or non-A non-B hepatitis. 
compared with patients who did not experience posttrans-
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Table 1. Incidence of Posttransplant Hepatitis and Chronic Relection In Study Population 
HBV hepatitis 
Non·A non·B 
Hepatitis 
PBC·PSC 
PNC·E 
Tumor 
Cryptogenic 
Other 
Total 
Pretransplant 
DiagnosIs 
(%) 
43 (7) 
64 (10) 
157(25) 
94(15) 
7B (13) 
112 (lB) 
70 (11) 
61B (100) 
'At 415 :: 379 days altar OlT. 
'At 48 :: 42 days alter OlT. 
'At 528 :: 398 days altar OlT. 
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Posttransplant BlNon·A 
Non·S Hepatitis 
(%)' 
39/43 (91) 
40/64 (63) 
14/157 (9) 
6/194 (6) 
9nB(12) 
20/112 (1B) 
2nO(3) 
130 (21)'''' 
CMV Hepatitis (%)t 
5/47 (11) 
9/67 (13) 
20/157 (13) 
lB/94 (19) 
1Bn6(23) 
6/112 (5) 
12nO(17) 
BB (14) 
Chronic 
Rejection (%)' 
17147 (36) 
26167 (39) 
25/157 (16) 
11/94 (12) 
10nB (13) 
251112 (23) 
6nO(9) 
1 lB (19) 
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Fig 1. Three-year patient survival in patients with and without 
chronic rejection. 
plant hepatitis. The incidence of chronic rejection was 35cr 
(17 of 48) in patients with hepatitis Band 567C (46 of 82) in 
patients with non-A, non-B hepatitis (P < .05). Posttrans-
plant hepatitis was diagnosed before chronic rejection in 
59% of patients. at the same time in 31 %, and after chronic 
rejection in 10%. 
Overall the immunosuppression as measured by eyA 
dose, level. and prednisone dose was not significantly 
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Fig 2. Three-year graft survival in patients with and without 
chronic rejection. 
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different among those patients who did or did not develop 
chronic rejection. Onlv the level of evA at 360 davs after 
OL T and the dose of' CvA at no d;vs were silwificantlv 
higher in those patients 'who develop~d chronic" rejectio~ 
(P < .05). 
DISCUSSION 
In the present study. the development of posttransplant B. 
non-A non-B. and CMY hepatitis has been associated with 
a significantly higher incidence of chronic rejection after 
OL T. We were concerned that chronic rejection had devel-
oped in patients transplanted for the diagnosis of hepatitis 
because of a systematic error in baseline immunosuppres-
sion. To explore this possibility we looked at the evA dose 
and level and prednisone dose for patients stratified-by their 
pretransplant diagnosis. Patients with hepatitis received 
equivalent immunosuppression to patients transplanted for 
all other indications. 
On the other hand. some of the pathologic features of 
chronic rejection have been previously associated with 
hepatitis. particularly non-A non-B. in patients who did not 
receive transplants.'I.lu Thus. we must consider the possibil-
ity that HBY. Hey. and/or CMY viruses. or the ce\l-
mediated immune responses against them. have a direct 
role in the pathogenesis of chronic rejection after OL T. 
Because there is no satisfactory therapy for HBY and Hey 
hepatitis after transplantation. a reevaluation of baseline 
immunosuppression should be considered in this high-risk 
population. 
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